George Health was established to commercialise the research of The George Institute for Global Health, one of the world’s leading medical research institutes in non-communicable diseases. This outstanding knowledge base means that George Health can provide not only fast, affordable, simple and scalable new treatments for patients, but also exciting investment opportunities combining strong commercial returns with real social impact.
There is increasing demand for new treatments and ways to manage chronic disease, driven by a growing ageing population and lack of access to appropriate medical treatments and services globally.
To meet this need, George Health has four established businesses that are poised for signiﬁcant growth, and integrated in a way that enables innovative health products and services to be taken all the way from concept to market, in a relatively short time frame. This capability is usually only available within big pharma or medical technology companies.
George Health has exclusive commercial rights to all intellectual property of The George Institute, as well as exclusive access to the expertise and support of the Institute. The Institute’s focus on late stage clinical research for chronic disease means that medicines and technologies are proven before George Health commercialises, resulting in a much higher probability of success rate than is usual in the industry.
An experienced management team leads George Health with a long industry track record in drug development and commercialisation, biotechnology, healthcare delivery and venture capital investment in established and emerging markets. Coupled with the global scientific leadership of The George Institute, our business has potential for real social and economic impact.